Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain

摘要

BackgroundThe objective of the study was to analyse whether azacitidine is a cost-effective option for the treatment of myelodysplastic syndrome in the Spanish setting compared with conventional care regimens, including best supportive care, low dose chemotherapy and standard dose chemotherapy.